Skip to content
DataLookout
Menu

AWAKENNCT07819435

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 2 of 63 sites
  2. Minor Site details revised at 6 of 63 sites
  3. Minor Trial sites expanded: 22 → 63 locations
  4. Notable Recruitment opened
    • Trial sites expanded: 17 → 22 locations
    • Trial sites expanded: 0 → 17 locations
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 17
    • Start date changed from estimate of Sep 2026 to Sep 21, 2026
  6. Minor Study title shortened, about 4 words
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in non-vellus target area hair count
Timeframe: Week 24

Secondary (3)

Change from baseline in the Participant Assessment of Scalp Coverage
≥20% increase from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count

Arms and interventions

PP405 0.05% Topical GelExperimental

PP405 applied to the scalp from Day 1 to Week 24; then continuing PP405 from Week 24 to Week 52.

Vehicle Topical GelPlacebo comparator

Vehicle applied to the scalp from Day 1 to Week 24; then re-randomized 1:1 to receive either PP405 or vehicle QD from Week 24 to Week 52

Drugs: PP405 0.05% Topical Gel, Vehicle Topical Gel

Sites

63 sites in 2 countries

United States 57, Canada 6